(Q37776590)

23 August 2017

1 reference

title

Chagas disease: changes in knowledge and management (English)

1 reference

23 August 2017

0 references

François-Xavier Lescure

1

1 reference

23 August 2017

Guillaume Le Loup

2

1 reference

23 August 2017

Hector Freilij

3

1 reference

23 August 2017

Michel Develoux

4

1 reference

23 August 2017

Luc Paris

5

1 reference

23 August 2017

Laurent Brutus

6

1 reference

23 August 2017

Gilles Pialoux

7

1 reference

23 August 2017

language of work or name

1 reference

1 August 2010

1 reference

Lancet Infectious Diseases

23 August 2017

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

8

1 reference

23 August 2017

page(s)

556-570

1 reference

on focus list of Wikimedia project

23 August 2017

ScienceSource

0 references

cites work

The Genome Sequence of Trypanosoma cruzi, Etiologic Agent of Chagas Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

The Trypanosoma cruzi proteome.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Can wild Triatoma infestans foci in Bolivia jeopardize Chagas disease control efforts?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Reinfestation sources for Chagas disease vector, Triatoma infestans, Argentina

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

High resistance to pyrethroid insecticides associated with ineffective field treatments in Triatoma infestans (Hemiptera: Reduviidae) from Northern Argentina

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Epidemiological evaluation of Chagas disease in a rural area of southern Bolivia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Sustainable vector control and management of Chagas disease in the Gran Chaco, Argentina

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Congenital Chagas disease: diagnostic and clinical aspects in an area without vectorial transmission, Bermejo, Bolivia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Safety of the blood supply in Latin America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Chagas disease in the Amazon region.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Chagas disease in Mexico: an analysis of geographical distribution during the past 76 years--a review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Blood transfusion and iatrogenic risks in Mexico City. Anti-Trypanosoma cruzi seroprevalence in 43,048 blood donors, evaluation of parasitemia, and electrocardiogram findings in seropositive

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Chagas' disease in Mexico

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Chagas disease transmission in periurban communities of Arequipa, Peru

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Antibodies to Trypanosoma cruzi among blood donors in Buenos Aires, Argentina

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Triatoma infestans in Greater Buenos Aires, Argentina.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Epidemiology of Chagas disease in non-endemic countries: the role of international migration.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Prognostic impact of Chagas disease in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Chagas disease in a domestic transmission cycle, southern Texas, USA

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Distribution and characterization of canine Chagas disease in Texas

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Transmission of Trypanosoma cruzi by heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Mother-to-child transmission of Chagas' disease in North America: why don't we do more?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

The sero-prevalence of antibodies to trypanosoma cruzi in Latin American refugees and immigrants to Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Prevalence and vertical transmission of Trypanosoma cruzi infection among pregnant Latin American women attending 2 maternity clinics in Barcelona, Spain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Chagas disease, France

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Prevalence, clinical staging and risk for blood-borne transmission of Chagas disease among Latin American migrants in Geneva, Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Chagas cardiomyopathy: Europe is not spared!

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Seroprevalence ofTrypanosoma cruziinfection in at-risk blood donors in Catalonia (Spain)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Testing blood donors for Chagas disease in the Paris area, France: first results after 18 months of screening

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Current concepts in immunoregulation and pathology of human Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Chagas heart disease pathogenesis: one mechanism or many?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Parasite persistence in the aetiology of Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Association of an increase in CD8+ T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

The molecular epidemiology and phylogeography of Trypanosoma cruzi and parallel research on Leishmania: looking back and to the future.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Mechanism of genetic exchange in American trypanosomes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Alternative lifestyles: the population structure of Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Molecular identification of Trypanosoma cruzi I tropism for central nervous system in Chagas reactivation due to AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Differential expression of a virulence factor, the trans-sialidase, by the main Trypanosoma cruzi phylogenetic lineages

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Vaccination approaches against Trypanosoma cruzi infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Immune system recognition of Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Analysis of the cellular immune response in patients with the digestive and indeterminate forms of Chagas' disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Functional IL‐10 Gene Polymorphism Is Associated with Chagas Disease Cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

BAT1,a Putative Anti‐Inflammatory Gene, Is Associated with Chronic Chagas Cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Association between IL-1B and IL-1RN gene polymorphisms and Chagas' disease development susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

TNF gene polymorphisms are associated with reduced survival in severe Chagas' disease cardiomyopathy patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

HLA and β-myosin heavy chain do not influence susceptibility to Chagas' disease cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Distribution of HLA-DRB1 alleles in Argentinean patients with Chagas' disease cardiomyopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Pivotal role for TGF-beta in infectious heart disease: The case of Trypanosoma cruzi infection and consequent Chagasic myocardiopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Clinical and epidemiological aspects of Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Cardiac involvement in African and American trypanosomiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Chagas disease: clinical aspects and treatment in non-endemic countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: a marker of disease severity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Dysautonomia and ventricular dysfunction in the indeterminate form of Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Early detection of left ventricular diastolic dysfunction in Chagas' disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Minor segmental wall motion abnormalities detected in patients with Chagas' disease have adverse prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Sudden cardiac death in Chagas' heart disease in the contemporary era.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Stroke: a neglected complication of American trypanosomiasis (Chagas' disease).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

1 reference

7 January 2021

[Development of chronic human chagas cardiopathy in the hinterland of the Paraíba State, Brazil, in a 4.5 year period]

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Chagas disease is an independent risk factor for stroke: baseline characteristics of a Chagas Disease cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Ischemic cerebrovascular events in patients with Chagas cardiomyopathy: a prospective follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Risk factors and consequences of congenital Chagas disease in Yacuiba, south Bolivia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Maternal Trypanosoma cruzi infection, pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected newborns in Bolivia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Congenital transmission of Trypanosoma cruzi is associated with maternal enhanced parasitemia and decreased production of interferon- gamma in response to parasite antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Direct molecular profiling of minicircle signatures and lineages of Trypanosoma cruzi bloodstream populations causing congenital Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Are maternal re-infections with Trypanosoma cruzi associated with higher morbidity and mortality of congenital Chagas disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Transmission of Tropical and Geographically Restricted Infections during Solid-Organ Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Risk factors for Chagas' disease reactivation after heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Chagas disease in bone marrow transplantation: an approach to preemptive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Usefulness of PCR strategies for early diagnosis of Chagas' disease reactivation and treatment follow-up in heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Reactivation of Chagas disease with central nervous system involvement in HIV-infected patients in Argentina, 1992-2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Trypanosoma cruzi parasitemia in chronic Chagas disease: comparison between human immunodeficiency virus (HIV)-positive and HIV-negative patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Long-term follow-up of co-infected HIV and Trypanosoma cruzi Brazilian patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Chagasic encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

[Chronic Chagas' disease: from xenodiagnosis and hemoculture to polymerase chain reaction]

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Enzyme-linked immunosorbent assay for serological diagnosis of Chagas' disease employing a Trypanosoma cruzi recombinant antigen that consists of four different peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Assessment of chemiluminescence and PCR effectiveness in relation to conventional serological tests for the diagnosis of Chagas' disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Chagas’ disease diagnosis: comparative analysis of recombinant ELISA with conventional ELISA and the haemagglutination test

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

The validity of serologic tests for Trypanosoma cruzi and the effectiveness of transfusional screening strategies in a hyperendemic region

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Serological diagnosis of Trypanosoma cruzi: evaluation of three enzyme immunoassays and an indirect immunofluorescent assay.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Evaluation of a new Trypanosoma cruzi antibody assay for blood donor screening

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Evaluation of a new enzyme-linked immunosorbent assay for detection of Chagas antibody in US blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Chagas' disease diagnosis: a multicentric evaluation of Chagas Stat-Pak, a rapid immunochromatographic assay with recombinant proteins of Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Validation of a rapid and reliable test for diagnosis of chagas' disease by detection of Trypanosoma cruzi-specific antibodies in blood of donors and patients in Central America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Field evaluation of a rapid immunochromatographic assay for detection of Trypanosoma cruzi infection by use of whole blood

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Sensitivity and specificity of Chagas Stat-Pak test in Bolivia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Chagas' disease diagnosis: comparative analysis of parasitologic, molecular, and serologic methods

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Trypanosoma cruzi recombinant complement regulatory protein: a novel antigen for use in an enzyme-linked immunosorbent assay for diagnosis of Chagas' disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Blood culture and polymerase chain reaction for the diagnosis of the chronic phase of human infection with Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

PCR assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Comparación de una prueba de PCR basada en los genes codificantes para la histona H2A/SIRE con pruebas serológicas convencionales para el diagnóstico de la enfermedad de Chagas crónica en pacientes colombianos

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Polymerase chain reaction for chronic Trypanosoma cruzi infection yields higher sensitivity in blood clot than buffy coat or whole blood specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Development and validation of a risk score for predicting death in Chagas' heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Clinical predictors of chronic chagasic myocarditis progression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Exercise stress testing as a predictor of progression of early chronic Chagas heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Prognostic implications of clinical, electrocardiographic and hemodynamic findings in chronic Chagas' disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

The treatment of Chagas disease (South American trypanosomiasis)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Prognostic value of QT interval parameters for mortality risk stratification in Chagas' disease: results of a long-term follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Predictors of mortality in chronic Chagas disease: a systematic review of observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Cardiovascular magnetic resonance assessment of ischemic and nonischemic cardiomyopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Clinical aspects of the Chagas' heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Echocardiography in Chagas heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Left ventricular cineangiography in Chagas' disease: detection of early myocardial damage

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

[Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation]

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Evaluation and treatment of chagas disease in the United States: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Control of Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

The challenges of Chagas Disease-- grim outlook or glimmer of hope

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

American trypanosomiasis (Chagas' disease) and the role of molecular epidemiology in guiding control strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Trypanosomiasis vector control in Africa and Latin America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

Cost-effectiveness of Chagas disease interventions in latin america and the Caribbean: Markov models.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

[Epidemiological, clinical and parasitological aspects of Chagas' disease in Mato Grosso do Sul State]

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970098-0

7 January 2021

10.1016/S1473-3099(10)70098-0

Identifiers

DOI

1 reference

23 August 2017

1 reference